-+ 0.00%
-+ 0.00%
-+ 0.00%

Radiopharm starts first-in-human Phase 1 trial of RAD 402 in advanced prostate cancer

PUBT·04/23/2026 11:12:32
Listen to the news
Radiopharm starts first-in-human Phase 1 trial of RAD 402 in advanced prostate cancer
  • Radiopharm completed enrollment in Phase 2b imaging trial of 18F-RAD101 in recurrent brain metastases, building on interim results already presented that supported performance versus MRI.
  • Management flagged that confirmation of these findings would trigger preparation for a multi-center, multi-country Phase 3 registrational study.
  • Initial Phase 0/1 data for 177Lu-RAD202 were presented at AACR 2026, showing encouraging tumor targeting with tolerability that supported further dose escalation.
  • Radiopharm initiated two first-in-human studies, dosing first patients in Lu177-RV-01 across various tumor types and Tb161-RAD402 in advanced prostate cancer.
  • Company guided to additional RAD202 and RAD204 dose-cohort readouts in mid-2026, setting up near-term clinical catalysts for pipeline valuation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604230700PRIMZONEFULLFEED1001177441) on April 23, 2026, and is solely responsible for the information contained therein.